BARTEK-INGREDIENTS
25.1.2023 21:05:42 CET | Business Wire | Press release
Bartek Ingredients advances its plans to strengthen its position as the world’s largest producer of malic and food-grade fumaric acid with the groundbreaking of its state-of-the-art, $175 million malic and fumaric acid production facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005653/en/
Left to right: Tim Larson (Bartek), Minister Neil Lumsden, MP Chad Collins, Minister Lisa Thompson, Hamid Goli (Bartek), Jose Kafie (Bartek), John Burrows (Bartek), Jim Vincent (Bartek), Steven Chambers (Bartek), Minister Vic Fedeli. (Photo: Business Wire)
The company held a groundbreaking ceremony on Jan. 12 with Canadian government officials and local community leaders to celebrate the official commencement of the construction project.
“We are thrilled to be breaking ground on our new facility which will set a new global benchmark for safety, efficiency, and environmental performance,” Bartek President and CEO John Burrows said. “We are pleased to be investing in the community of Stoney Creek and proud to play an integral part in supporting local industries and the local economy. We are thankful for our partnerships with the provincial and federal government and Environment Hamilton and their support and guidance throughout the process.”
Among those in attendance at the groundbreaking were Neil Lumsden, Minister of Tourism, Culture and Sport and Member of Provincial Parliament for Hamilton East, Victor Fedeli, Minister of Economic Development and Trade, Lisa Thompson, Minister of Agriculture, Food and Rural Affairs, and Chad Collins, Member of Federal Parliament for Hamilton East-Stoney Creek.
“Congratulations to everyone at Bartek Ingredients on this exciting milestone,” Minister Fedeli said. “Bartek’s $175 million investment will ensure that the company can continue to expand and create more good-paying jobs in Hamilton and the surrounding region. Together, we’re building a stronger Ontario with opportunities for all people.”
The facility will double Bartek’s production capacity and propel new product development and other innovation efforts. It is also being built with sustainability in mind and is expected to be the most environmentally sustainable facility in the industry – projected to reduce per unit greenhouse gas emissions by more than 80 percent.
“Ontario has a clean energy advantage and is a sustainable and predictable place to do business,” Minister Piccini said. “As a result, we’re attracting the jobs of tomorrow. My Ministry was proud to work closely with Bartek through the permitting and approvals process to help secure this significant investment to Ontario.”
Minister Thompson added: “Bartek’s new state-of-the-art facility will be a shining example of Ontario’s robust agri-food manufacturing and processing sector. This major investment will create good-paying jobs in the local community and further strengthen Ontario’s value-added food supply chain.”
Through this project, Bartek will inject $100 million into the local Stoney Creek economy. The facility is expected to be fully operational at the beginning of 2024.
“Hamilton’s Bartek facility will soon become one of the world’s largest malic and food-grade acid production plants,” Minister Lumsden said. “Our government is excited to see local manufacturers, such as Bartek, invest in Ontario to grow and create more good-paying jobs right here in Hamilton!”
For more information, please visit bartek.ca or contact Bartek at info@bartek.ca.
About Bartek Ingredients
For over 50 years, Bartek Ingredients Inc. has been a leading global manufacturer of malic acid, fumaric acid, and maleic anhydride. Headquartered in Stoney Creek, Ontario, Canada, Bartek employs 120 people across its two production facilities in Southern Ontario. Bartek’s facilities are registered to the ISO 9001:2015 Standard. Bartek also holds the BRC Global Standard for Food Safety certification, and it distributes to more than 40 countries around the world. With new ownership in 2019 and significant investments, Bartek’s presence in the food and beverage space continues to be bolstered by highly innovative products and services that utilize deep product expertise and application knowledge to offer solutions to industry needs. For more information about Bartek, visit bartek.ca/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005653/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom